News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Recro Pharma (REPH) Announces Closing Of Initial Public Offering



3/13/2014 9:30:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MALVERN, Pa., March 12, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, today announced the closing of its previously announced initial public offering of 3,750,000 shares of common stock at a public offering price of $8.00 per share. In connection with this offering, the underwriters exercised in full their option to purchase an additional 562,500 shares of common stock from the company. Total gross proceeds from the offering were $34,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the company.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES